Novartis still sees EU submissions for Galvus, Rasilez before end ...

Forbes - USA
... Novartis added that FTY720, an oral once-daily treatment for relapsing forms of multiple sclerosis, is currently in Phase III development and US and EU ...

Novartis Generates Strong Sales and Earnings Growth in the First ...
PharmaLive.com (press release) - Newtown,PA,USA
... the completion in 2005 of several Phase III trials and ahead of anticipated investments during the second half of 2006, including for FTY720 (multiple sclerosis ...

Drug firm Novartis books $1.7B
CNN International - USA
... Novartis also said its FTY720 oral once-daily treatment for multiple sclerosis had recently started final Phase III clinical studies. ...